Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Imc, Kamerling"'
Autor:
Ac, Dijkmans, Sg, Kuiper, Burggraaf J, Jw, Mouton, Eb, Wilms, Dj, Touw, Stevens J, Cees van Nieuwkoop, Imc, Kamerling
Publikováno v:
Europe PubMed Central
Fosfomycin is a broad-spectrum antibiotic agent used orally for uncomplicated cystitis. The intravenous form of administration has recently been authorised in the Netherlands.- Thanks to its broad spectrum and extensive tissue penetration, fosfomycin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1183c1936eed4006dd7390cfbe448256
https://pubmed.ncbi.nlm.nih.gov/28612692
https://pubmed.ncbi.nlm.nih.gov/28612692
Autor:
Gabriel E. Jacobs, Imc Kamerling, J. van Pelt, Frans G. Zitman, Jma van Gerven, Roel H. DeRijk, ML de Kam
Publikováno v:
Journal of Psychopharmacology, 24(1), 65-72
A recently developed oral serotonergic challenge test consisting of 5-Hydroxytryptophane (5-HTP, 200 mg) combined with carbidopa (CBD, 100 mg + 50 mg) exhibited dose-related neuroendocrine responsiveness and predictable pharmacokinetics. However, its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3483a5e10a324cdfa72ae94e881ae10
https://doi.org/10.1177/0269881108094299
https://doi.org/10.1177/0269881108094299
Autor:
L, Kervezee, V, Gotta, J, Stevens, W, Birkhoff, Imc, Kamerling, M, Danhof, J H, Meijer, J, Burggraaf
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Understanding the factors influencing a drug's potential to prolong the QTc interval on an electrocardiogram is essential for the correct evaluation of its safety profile. To explore the effect of dosing time on drug-induced QTc prolongation, a rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd3f988d4c39e1514cfb542589aa34ee
https://pubmed.ncbi.nlm.nih.gov/28142221
https://pubmed.ncbi.nlm.nih.gov/28142221
Autor:
van der Plas JL; Centre for Human Drug Research, Leiden, the Netherlands; Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: JvdPlas@chdr.nl., Haijema BJ; Mucosis B.V., Groningen, the Netherlands; 3D-PharmXchange, Tilburg, the Netherlands., Leenhouts K; Mucosis B.V., Groningen, the Netherlands; Allero Therapeutics B.V., Rotterdam, the Netherlands., Paul Zoeteweij J; Viroclinics Biosciences B.V., Rotterdam, the Netherlands., Burggraaf J; Centre for Human Drug Research, Leiden, the Netherlands; Leiden Academic Centre for Drug Research, Leiden, the Netherlands., Kamerling IMC; Centre for Human Drug Research, Leiden, the Netherlands; Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
Publikováno v:
Vaccine [Vaccine] 2024 Sep 17; Vol. 42 (22), pp. 125836. Date of Electronic Publication: 2024 May 20.
Autor:
Cárdenas V; Janssen Research & Development LLC, Spring House, PA, United States. Electronic address: cardenasv@yahoo.com., Le Gars M; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: Mathieu.legars1@gmail.com., Truyers C; Janssen Research & Development, Beerse Belgium. Electronic address: ctruyers@its.jnj.com., Ruiz-Guiñazú J; Janssen Research & Development, Beerse Belgium. Electronic address: JRuizGui@its.jnj.com., Struyf F; Janssen Research & Development, Beerse Belgium. Electronic address: fstruyf@gmail.com., Colfer A; Janssen Research & Development LLC, Spring House, PA, United States. Electronic address: acolfer@its.jnj.com., Bonten M; Julius Center for Health Services and Primary Care, UMC Utrecht, Utrecht University and European Clinical Alliance on Infectious Diseases, Utrecht, the Netherlands. Electronic address: m.j.m.bonten@umcutrecht.nl., Borobia A; Clinical Pharmacology Department, La Paz University Hospital. School of Medicine, Universidad Autónoma de Madrid, IdiPAZ. CIBERINFECT, Spain. Electronic address: alberto.borobia@salud.madrid.org., Reisinger EC; Rostock University Medical Center, Dept. of Infectious Diseases and Tropical Medicine, Rostock, Germany. Electronic address: emil.reisinger@uni-rostock.de., Kamerling IMC; Centre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, the Netherlands. Electronic address: idvisser@chdr.nl., Douoguih M; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: macaya.douoguih@merck.com., Sadoff J; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: Jerry@Centivax.com.
Publikováno v:
Vaccine [Vaccine] 2024 Jun 11; Vol. 42 (16), pp. 3536-3546. Date of Electronic Publication: 2024 May 04.
Autor:
Prins MLM; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Roozen GVT; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands., Pothast CR; Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands., Huisman W; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands., van Binnendijk R; Department of Immune Surveillance, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., den Hartog G; Department of Immune Surveillance, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.; Laboratory of Medical Immunology, RadboudUMC, Nijmegen, The Netherlands., Kuiper VP; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands., Prins C; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Janse JJ; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands., Lamers OAC; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands., Koopman JPR; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands., Kruithof AC; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.; Center for Human Drug Research, Leiden, The Netherlands., Kamerling IMC; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.; Center for Human Drug Research, Leiden, The Netherlands., Dijkland RC; Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands., de Kroon AC; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands., Azimi S; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands., Feltkamp MCW; Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands., Kuijer M; Department of Immune Surveillance, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Jochems SP; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands., Heemskerk MHM; Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands., Rosendaal FR; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands., Roestenberg M; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands., Visser LG; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Roukens AHE; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. a.h.e.roukens@lumc.nl.
Publikováno v:
NPJ vaccines [NPJ Vaccines] 2024 Jan 02; Vol. 9 (1), pp. 1. Date of Electronic Publication: 2024 Jan 02.
Autor:
van der Plas JL; Centre for Human Drug Research, Leiden, Netherlands; Department of Infectious Diseases and Parasitology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Kuiper VP; Department of Infectious Diseases and Parasitology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Bagchus WM; Merck Institute for Pharmacometrics, Merck Serono (an affiliate of Merck KGaA, Darmstadt, Germany), Lausanne, Switzerland., Bödding M; The healthcare business of Merck KGaA, Darmstadt, Germany., Yalkinoglu Ö; The healthcare business of Merck KGaA, Darmstadt, Germany., Tappert A; The healthcare business of Merck KGaA, Darmstadt, Germany., Seitzinger A; The healthcare business of Merck KGaA, Darmstadt, Germany., Spangenberg T; Global Health Institute of Merck, Ares Trading (a subsidiary of Merck KGaA, Darmstadt, Germany), Eysins, Switzerland., Bezuidenhout D; Merck (Pty) (an affiliate of Merck KGaA, Darmstadt, Germany), Modderfontein, South Africa., Wilkins J; Occams, Amstelveen, Netherlands., Oeuvray C; Global Health Institute of Merck, Ares Trading (a subsidiary of Merck KGaA, Darmstadt, Germany), Eysins, Switzerland., Dhingra SK; Hemogenyx Pharmaceuticals, New York, NY, USA., Thathy V; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, USA., Fidock DA; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, USA; Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA., Smidt LCA; Centre for Human Drug Research, Leiden, Netherlands., Roozen GVT; Department of Infectious Diseases and Parasitology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Koopman JPR; Department of Infectious Diseases and Parasitology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Lamers OAC; Department of Infectious Diseases and Parasitology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Sijtsma J; Department of Infectious Diseases and Parasitology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., van Schuijlenburg R; Department of Infectious Diseases and Parasitology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Wessels E; Department of Medical Microbiology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Meij P; Center for Cell and Gene Therapy, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Kamerling IMC; Centre for Human Drug Research, Leiden, Netherlands; Department of Infectious Diseases and Parasitology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Roestenberg M; Department of Infectious Diseases and Parasitology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands. Electronic address: m.roestenberg@lumc.nl., Khandelwal A; The healthcare business of Merck KGaA, Darmstadt, Germany.
Publikováno v:
The Lancet. Infectious diseases [Lancet Infect Dis] 2023 Oct; Vol. 23 (10), pp. 1164-1174. Date of Electronic Publication: 2023 Jul 03.
Autor:
In 't Veld AE; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Centre, Leiden, The Netherlands., Grievink HW; Centre for Human Drug Research, Leiden, The Netherlands.; Division of BioTherapeutics, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands., van der Plas JL; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Centre, Leiden, The Netherlands., Eveleens Maarse BC; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Centre, Leiden, The Netherlands., van Kraaij SJW; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Centre, Leiden, The Netherlands., Woutman TD; Centre for Human Drug Research, Leiden, The Netherlands., Schoonakker M; Centre for Human Drug Research, Leiden, The Netherlands., Klarenbeek NB; Centre for Human Drug Research, Leiden, The Netherlands., de Kam ML; Centre for Human Drug Research, Leiden, The Netherlands., Kamerling IMC; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Centre, Leiden, The Netherlands., Jansen MAA; Centre for Human Drug Research, Leiden, The Netherlands., Moerland M; Centre for Human Drug Research, Leiden, The Netherlands. mmoerland@chdr.nl.; Leiden University Medical Centre, Leiden, The Netherlands. mmoerland@chdr.nl.
Publikováno v:
Immunologic research [Immunol Res] 2023 Aug; Vol. 71 (4), pp. 617-627. Date of Electronic Publication: 2023 Feb 22.
Autor:
Prins MLM; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., van der Plas JL; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.; Centre for Human Drug Research, Leiden, The Netherlands., Vissers MFJM; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Center, Leiden, The Netherlands., Berends CL; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Center, Leiden, The Netherlands., Tresch G; Molecular Partners AG, Schlieren, Switzerland., Soergel M; Molecular Partners AG, Schlieren, Switzerland., Fernández E; Molecular Partners AG, Schlieren, Switzerland., van den Berge N; Municipal Health Services (GGD Hollands Midden), Leiden, The Netherlands., Duijsings D; Viroclinics Biosciences B.V., Rotterdam, The Netherlands., Zitt C; Molecular Partners AG, Schlieren, Switzerland., Stavropoulou V; Molecular Partners AG, Schlieren, Switzerland., Zimmermann M; Molecular Partners AG, Schlieren, Switzerland., Drake RF; Molecular Partners AG, Schlieren, Switzerland., Burggraaf J; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Center, Leiden, The Netherlands., Groeneveld GH; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Kamerling IMC; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.; Centre for Human Drug Research, Leiden, The Netherlands.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2023 Mar; Vol. 89 (3), pp. 1105-1114. Date of Electronic Publication: 2022 Oct 24.
Autor:
Vrouwe JPM; Centre for Human Drug Research, Zernikedreef 8, Leiden, 2333 CL, the Netherlands; Leiden University Medical Center (LUMC), Albinusdreef 2, Leiden, 2333 ZA, the Netherlands., Meulenberg JJM; Department of Oncology, Arthrogen B.V., Meibergdreef 45, Amsterdam, 1005BA, the Netherlands., Klarenbeek NB; Centre for Human Drug Research, Zernikedreef 8, Leiden, 2333 CL, the Netherlands; Leiden University Medical Center, Department of Internal Medicine, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands., Navas-Cañete A; Leiden University Medical Center, Department of Radiology, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands. Electronic address: a.navas_canete@lumc.nl., Reijnierse M; Leiden University Medical Center, Department of Radiology, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands., Ruiterkamp G; Department of Oncology, Arthrogen B.V., Meibergdreef 45, Amsterdam, 1005BA, the Netherlands., Bevaart L; Department of Oncology, Arthrogen B.V., Meibergdreef 45, Amsterdam, 1005BA, the Netherlands., Lamers RJ; Department of Oncology, Arthrogen B.V., Meibergdreef 45, Amsterdam, 1005BA, the Netherlands., Kloppenburg M; Leiden University Medical Center, Department of Rheumatology, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands., Nelissen RGHH; Leiden University Medical Center, Department of Orthopaedics, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands., Huizinga TWJ; Leiden Academic Centre for Drug Research, PO box 9500, Leiden, 2300 RA, the Netherlands., Burggraaf J; Centre for Human Drug Research, Zernikedreef 8, Leiden, 2333 CL, the Netherlands; Leiden University Medical Center, Department of Internal Medicine, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands; Leiden Academic Centre for Drug Research, PO box 9500, Leiden, 2300 RA, the Netherlands., Kamerling IMC; Centre for Human Drug Research, Zernikedreef 8, Leiden, 2333 CL, the Netherlands; Leiden University Medical Center, Department of Infectious Diseases, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands. Electronic address: idevisser@chdr.nl.
Publikováno v:
Osteoarthritis and cartilage [Osteoarthritis Cartilage] 2022 Jan; Vol. 30 (1), pp. 52-60. Date of Electronic Publication: 2021 Oct 06.